Investigating the Clinical Consequences of Flutemetamol-PET-scanning
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Alzheimer's disease; Dementia; Diagnostic-imaging-abnormalities; Mild cognitive impairment
- Focus Diagnostic use
- 26 Oct 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
- 23 Mar 2016 No of arms changed from 2 to 1 as per ClinicalTrials.gov record.
- 23 Mar 2016 Planned number of patients changed from 160 to 100 as per ClinicalTrials.gov record.